Stock listing
NASDAQ:HOWL Werewolf Therapeutics, Inc. Stock
Home listing (NASDAQ) of Werewolf Therapeutics, Inc.
Follow Werewolf Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:HOWL
$0.947 USD -0.083 (-8.1%)
Close on Nov 20, 2026
- Day range
- $0.930 – $0.990 USDNov 20, 2026
- Volume
- 373,048 sharesNov 20, 2026
- Market cap
- $46.01M USDAt the close on Nov 20, 2026 · price × 48.60M shares outstanding
- 52-week range
- $0.270 – $1.200 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5.43M USDMedian day 477,440 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:HOWL · Home | $0.947 USD | -0.083 (-8.1%) | 373,048 | $0.955 | $0.990 | $0.930 | $1.030 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:HOWL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.947 | -0.083 | -8.1% | $0.955 | $0.990 | $0.930 | 373,048 | |
| $1.030 | -0.020 | -1.9% | $1.050 | $1.150 | $0.980 | 1,850,429 | |
| $1.050 | +0.059 | +6.0% | $0.968 | $1.050 | $0.965 | 1,083,152 | |
| $0.991 | +0.011 | +1.1% | $0.975 | $1.010 | $0.950 | 724,982 | |
| $0.980 | +0.000 | 0.0% | $0.980 | $1.010 | $0.980 | 317,207 | |
| $0.980 | -0.009 | -0.9% | $1.000 | $1.003 | $0.978 | 151,666 | |
| $0.989 | +0.019 | +1.9% | $0.970 | $0.990 | $0.970 | 138,343 | |
| $0.970 | -0.040 | -4.0% | $1.010 | $1.010 | $0.970 | 217,806 | |
| $1.010 | 0.000 | 0.0% | $1.020 | $1.069 | $1.000 | 334,533 | |
| $1.010 | -0.010 | -1.0% | $1.020 | $1.030 | $0.983 | 176,558 | |
| $1.020 | -0.070 | -6.4% | $1.060 | $1.070 | $1.000 | 300,783 | |
| $1.090 | +0.020 | +1.9% | $1.080 | $1.100 | $1.050 | 301,354 | |
| $1.070 | +0.020 | +1.9% | $1.040 | $1.080 | $1.030 | 232,240 | |
| $1.050 | +0.064 | +6.5% | $0.986 | $1.060 | $0.986 | 272,009 | |
| $0.986 | -0.114 | -10.4% | $1.090 | $1.090 | $0.970 | 415,476 | |
| $1.100 | +0.040 | +3.8% | $1.080 | $1.100 | $1.050 | 398,718 | |
| $1.060 | +0.020 | +1.9% | $1.030 | $1.080 | $1.020 | 388,391 | |
| $1.040 | +0.059 | +6.1% | $0.990 | $1.050 | $0.960 | 306,791 | |
| $0.981 | +0.001 | +0.1% | $0.990 | $1.000 | $0.950 | 477,440 | |
| $0.980 | -0.030 | -3.0% | $1.010 | $1.030 | $0.980 | 209,936 | |
| $1.010 | -0.020 | -1.9% | $1.010 | $1.050 | $1.000 | 184,155 | |
| $1.030 | -0.020 | -1.9% | $1.050 | $1.060 | $1.010 | 199,374 | |
| $1.050 | +0.010 | +1.0% | $1.030 | $1.090 | $1.030 | 485,738 | |
| $1.040 | +0.060 | +6.1% | $0.979 | $1.055 | $0.979 | 378,846 | |
| $0.980 | -0.017 | -1.7% | $1.010 | $1.010 | $0.970 | 309,200 | |
| $0.997 | +0.017 | +1.7% | $0.962 | $1.018 | $0.962 | 426,200 | |
| $0.980 | -0.011 | -1.1% | $0.990 | $1.025 | $0.966 | 664,000 | |
| $0.991 | +0.009 | +0.9% | $1.000 | $1.010 | $0.970 | 353,200 | |
| $0.982 | +0.002 | +0.2% | $0.980 | $1.020 | $0.960 | 811,200 | |
| $0.980 | +0.070 | +7.7% | $0.930 | $0.990 | $0.920 | 704,600 | |
| $0.910 | -0.010 | -1.1% | $0.920 | $0.928 | $0.907 | 631,300 | |
| $0.920 | 0.000 | 0.0% | $0.916 | $0.925 | $0.908 | 381,600 | |
| $0.920 | -0.010 | -1.1% | $0.940 | $0.940 | $0.910 | 278,200 | |
| $0.930 | +0.002 | +0.2% | $0.930 | $0.950 | $0.910 | 237,700 | |
| $0.928 | +0.046 | +5.2% | $0.890 | $0.940 | $0.890 | 470,900 | |
| $0.882 | -0.040 | -4.3% | $0.920 | $0.925 | $0.881 | 299,000 | |
| $0.922 | +0.012 | +1.3% | $0.910 | $0.940 | $0.890 | 828,200 | |
| $0.910 | -0.020 | -2.2% | $0.940 | $0.950 | $0.880 | 970,500 | |
| $0.930 | -0.030 | -3.1% | $0.970 | $0.970 | $0.925 | 699,300 | |
| $0.960 | -0.021 | -2.1% | $0.975 | $0.983 | $0.960 | 454,900 | |
| $0.981 | -0.008 | -0.8% | $0.985 | $0.990 | $0.967 | 227,500 | |
| $0.989 | +0.007 | +0.7% | $0.974 | $0.990 | $0.970 | 316,500 | |
| $0.982 | +0.002 | +0.2% | $0.990 | $0.995 | $0.971 | 374,800 | |
| $0.980 | +0.015 | +1.6% | $0.985 | $0.990 | $0.960 | 475,600 | |
| $0.965 | +0.002 | +0.2% | $0.967 | $1.010 | $0.960 | 1,226,200 | |
| $0.963 | +0.044 | +4.8% | $0.940 | $0.980 | $0.935 | 583,900 | |
| $0.919 | -0.061 | -6.2% | $0.960 | $0.985 | $0.919 | 1,508,600 | |
| $0.980 | +0.022 | +2.3% | $0.951 | $0.982 | $0.923 | 1,202,700 | |
| $0.958 | -0.024 | -2.4% | $0.970 | $0.995 | $0.930 | 969,800 | |
| $0.982 | -0.007 | -0.7% | $0.970 | $1.020 | $0.960 | 549,000 | |
| $0.989 | +0.024 | +2.5% | $0.960 | $0.989 | $0.950 | 900,400 | |
| $0.965 | -0.015 | -1.5% | $0.975 | $0.990 | $0.950 | 867,100 | |
| $0.980 | +0.014 | +1.4% | $0.960 | $0.990 | $0.943 | 663,400 | |
| $0.966 | +0.022 | +2.3% | $0.940 | $0.967 | $0.930 | 487,400 | |
| $0.944 | -0.054 | -5.4% | $0.970 | $1.020 | $0.933 | 1,330,500 | |
| $0.998 | +0.040 | +4.2% | $0.943 | $0.998 | $0.940 | 1,303,700 | |
| $0.958 | +0.017 | +1.8% | $0.917 | $0.968 | $0.912 | 982,600 | |
| $0.941 | -0.002 | -0.2% | $0.935 | $0.949 | $0.900 | 1,268,300 | |
| $0.943 | -0.028 | -2.9% | $0.975 | $1.030 | $0.927 | 2,333,800 | |
| $0.971 | -0.018 | -1.8% | $0.990 | $0.998 | $0.914 | 2,217,800 | |
| $0.989 | +0.099 | +11.1% | $0.900 | $1.050 | $0.898 | 11,618,700 | |
| $0.890 | +0.007 | +0.8% | $0.866 | $0.934 | $0.840 | 6,432,712 | |
| $0.883 | +0.009 | +1.1% | $0.850 | $0.900 | $0.811 | 12,041,910 | |
| $0.874 | +0.443 | +102.8% | $0.980 | $1.050 | $0.860 | 296,734,500 | |
| $0.431 | +0.022 | +5.4% | $0.422 | $0.440 | $0.403 | 66,021,400 |
- Ticker
- NASDAQ:HOWL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
Latest deck · Nov 10, 2026
Merger or Acquisition (November 2026)
Merger or acquisition · 36 slides
Latest news
Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
Nov 9, 2026
Closed $1.01 (0.0%) on Nov 9, 2026
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
Oct 30, 2026
Closed $0.986 (-10.4%) on Oct 30, 2026
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Jul 31, 2026
Closed $0.353 (-29.4%) on Jul 31, 2026
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
May 7, 2026
Closed $0.68 (+9.7%) on May 8, 2026
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Mar 27, 2026
Closed $0.781 (-9.5%) on Mar 27, 2026
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
Feb 24, 2026
Closed $0.64 (-3.3%) on Feb 25, 2026
Werewolf Therapeutics Announces Pipeline and Business Updates
Dec 18, 2025
Closed $0.647 (-39.6%) on Dec 18, 2025
Werewolf Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 7 in the last 12 months · 67 in all · newest Nov 9, 2026 · oldest 2021
- Decks
- 10 decks · latest Nov 10, 2026
Where Werewolf Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:HOWL · Home listing · This page | NASDAQ | United States | USD |
| BOATS:HOWL | BOATS | United States | USD |
Valuation
Price/book 6.8× against a median of 5.1×: 7th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.14M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 6.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.55
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. · NASDAQ:HOWL | US$46.01M | US$4.14M | n/a | n/a | n/a | 6.8× | n/a | 0.0× | 1.55 |
| THX Pharma · EURONEXT:ALTHX | US$47.23M | US$30.92M | n/a | n/a | n/a | 14.5× | n/a | 0.9× | n/a |
| FluoGuide A/S · OMXSTO:FLUO | US$47.17M | US$43.89M | n/a | 5,538× | n/a | 10.5× | n/a | 0.9× | n/a |
| Rafael Holdings, Inc. · NYSE:RFL | US$47.10M | US$25.00M | n/a | 28.6× | n/a | 0.7× | n/a | 0.0× | 0.92 |
| Bio-fd&c Co. Ltd · KRX:251120 | US$46.73M | US$5.29M | 9.8× | 0.4× | 0.9× | 0.9× | 32.8% | 0.0× | n/a |
| Andros Pharmaceuticals Co., Ltd. · TPEX:6917 | US$46.01M | US$35.88M | n/a | 213× | n/a | 3.1× | −969.3% | 0.0× | n/a |
| MegaPro Biomedical Co., Ltd. · TPEX:6827 | US$45.95M | US$43.30M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| SunBio, Inc. · KRX:067370 | US$45.82M | US$42.92M | 14.2× | 4.6× | 8.9× | 2.0× | 34.6% | 0.0× | n/a |
| Apollomics Inc. · NASDAQ:APLM | US$45.28M | US$42.65M | n/a | 5.0× | n/a | n/a | −128.7% | n/a | 1.02 |
| Zelluna ASA · OSL:ZLNA | US$45.02M | US$38.83M | n/a | n/a | n/a | 5.1× | n/a | 0.0× | n/a |
| Oncoinvent ASA · OSL:ONCIN | US$44.76M | US$33.80M | n/a | 14.3× | n/a | 5.4× | −673.1% | 0.0× | n/a |
| Median of the others | US$45.98M | US$37.36M | 12.0× | 14.3× | 4.9× | 5.1× | −128.7% | 0.0× | 0.97 |
Forecasts
Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.89 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Daniel J. Hicklin | President, Chief Executive Officer, and Board member |
| Michael Urban | Vice President of Finance and Corporate Controller |
Board
| Director | Role |
|---|---|
| Anil Singhal | Board member |
| Briggs Morrison | Board member |
| Daniel J. Hicklin | President, Chief Executive Officer, and Board member |
| Meeta Chatterjee | Board member |
| Michael B. Atkins | Board member |
| Michael Sherman | Board member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · After close | +1.1% |
| Q2 2026 | Jul 31, 2026 · Before open | −29.4% |
| Q1 2026 | May 8, 2026 | +6.6% |
| Q4 2025 | Mar 27, 2026 · Before open | −9.5% |
| Q3 2025 | Nov 4, 2025 · Before open | −7.6% |
| Q2 2025 | Aug 14, 2025 · Before open | −2.2% |
| Q1 2025 | May 8, 2025 · Before open | −5.5% |
| Q4 2024 | Mar 11, 2025 | +0.4% |
| Q3 2024 | Nov 7, 2024 · Before open | −8.2% |
| Q2 2024 | Aug 8, 2024 · Before open | +8.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 3, 2024 · Before open | −0.2% |
| Q4 2023 | Mar 7, 2024 · Before open | −4.0% |
| Q3 2023 | Nov 14, 2023 · After close | 0.0% |
| Q2 2023 | Aug 10, 2023 · Before open | +4.0% |
| Q1 2023 | May 11, 2023 · Before open | −8.9% |
| Q4 2022 | Mar 23, 2023 · Before open | −5.2% |
| Q3 2022 | Nov 10, 2022 · Before open | +3.1% |
| Q2 2022 | Aug 11, 2022 · Before open | +14.0% |
| Q1 2022 | May 10, 2022 · Before open | +10.9% |
| Q4 2021 | Mar 24, 2022 · Before open | −4.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (November 2026) | Merger or acquisition | 36 slides | Nov 10, 2026 |
| Merger or Acquisition (August 2026) | Merger or acquisition | 24 slides | Aug 21, 2026 |
| Investor Presentation (December 2025) | Investor deck | 41 slides | Dec 18, 2025 |
| Investor Presentation (August 2025) | Investor deck | 46 slides | Aug 14, 2025 |
| Investor Presentation (May 2025) | Investor deck | 57 slides | May 8, 2025 |
| Investor Presentation (November 2024) | Investor deck | 53 slides | Nov 12, 2024 |
| ASCO 2024 | Conference | 24 slides | Jun 3, 2024 |
| Investor Presentation (January 2024) | Investor deck | 31 slides | Jan 8, 2024 |
| Technical Presentation (November 2023) | Technical | 15 slides | Nov 3, 2023 |
| Investor Presentation (September 2023) | Investor deck | 22 slides | Sep 18, 2023 |
IPO
Priced at US$16.00 a share on Apr 29, 2021.
- Price
- US$16.00 a share
- Shares offered
- 7,500,000 shares of common stock
- Offering size
- US$120 million
- Underwriters' option
- Up to 1,125,000 more shares
- Underwriters
- Jefferies, SVB Leerink, Evercore ISI, H.C. Wainwright & Co. · In the order on the cover
- Shares delivered
- On or about May 4, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 26, 2021 |
| Filed publicly | Apr 8, 2021 |
| Amended once | Apr 26, 2021 |
| Shares registered with an exchange | Apr 27, 2021 |
| Declared effective by the SEC | Apr 29, 2021 |
| Final prospectus, with the price | Apr 30, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 30, 2021 |
| EFFECT · Notice that a registration is effective | Apr 29, 2021 |
| S-1MEF · Registration of more shares for the same offering | Apr 29, 2021 |
| CERT · Exchange's certificate of listing | Apr 29, 2021 |
| CORRESP · Letter to the SEC | Apr 27, 2021 |
| CORRESP · Letter to the SEC | Apr 27, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 27, 2021 |
| S-1/A · Registration statement, amended | Apr 26, 2021 |
| CORRESP · Letter to the SEC | Apr 8, 2021 |
| S-1 · Registration statement | Apr 8, 2021 |
All 12 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Mar 29, 2021 |
| DRS · Draft registration statement | Feb 26, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 30, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1.89M | 19.9M | 16.4M | 4.15M | 0 | 0 |
| Cost of revenue | 1.63M | 1.81M | 1.76M | 2.51M | 735.0K | 777.0K | 463.0K |
| Gross profit | -1.63M | 71.0K | 18.2M | 16.4M | -735.0K | -777.0K | -463.0K |
| Research and development | 44.8M | 56.4M | 41.8M | 53.8M | 35.3M | 16.6M | 6.34M |
| Selling, general and administrative | 15.8M | 19.0M | 18.7M | 18.7M | 14.8M | 5.76M | 3.60M |
| Operating income | -60.7M | -73.6M | -40.5M | -56.1M | -50.1M | -22.4M | -9.94M |
| Depreciation and amortization | 1.63M | 1.81M | 1.76M | 1.10M | 216.0K | 150.0K | 25.0K |
| EBITDA | -59.0M | -71.8M | -38.7M | -55.0M | -49.9M | -22.3M | -9.91M |
| Interest expense | 5.27M | 4.66M | 3.14M | 0 | 216.0K | 101.0K | 372.0K |
| Income before tax | -60.8M | -70.5M | -37.4M | -53.8M | -50.0M | -15.0M | -10.2M |
| Income tax | 0 | 1.60M | -2.25M | -216.0K | -101.0K | 742.0K | |
| Net income | -60.8M | -70.5M | -37.4M | -53.8M | -50.0M | -15.0M | -11.0M |
| Earnings per share, basic | -1.32 | -1.63 | -1.05 | -1.86 | -10.94 | -28.08 | -0.38 |
| Earnings per share, diluted | -1.33 | -1.63 | -1.05 | -1.86 | -10.94 | -28.08 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 57.0M | 111.0M | 134.3M | 129.3M | 157.5M | 92.6M | 17.9M |
| Receivables | 1.35M | 6.93M | |||||
| Inventory | 2 | ||||||
| Current assets | 58.6M | 113.1M | 138.4M | 140.2M | 161.1M | 92.9M | 18.1M |
| Property, plant and equipment | 4.69M | 6.32M | 7.96M | 8.99M | 2.91M | 651.0K | 3.41M |
| Total assets | 69.4M | 126.9M | 174.8M | 160.2M | 179.3M | 96.4M | 21.7M |
| Accounts payable | 754.0K | 3.04M | 1.34M | 1.22M | 2.04M | 1.02M | 633.0K |
| Current liabilities | 36.1M | 15.2M | 19.4M | 24.0M | 11.9M | 5.28M | 2.04M |
| Long-term debt | 26.1M | 32.7M | |||||
| Total debt | 32.1M | 32.1M | 40.0M | 14.7M | 15.7M | 2.54M | 3.14M |
| Total liabilities | 44.6M | 53.5M | 63.5M | 37.9M | 26.5M | 7.18M | 11.9M |
| Shareholders' equity | 24.8M | 73.4M | 111.4M | 122.3M | 152.8M | -51.9M | 9.77M |
| Shares outstanding | 48.6M | 44.8M | 39.1M | 31.4M | 27.3M | 1.18M | 28.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -60.3M | -56.2M | -32.6M | -40.6M | -42.9M | -18.6M | -9.54M |
| Capital spending | 0 | -254.0K | -769.0K | -3.61M | -498.0K | -560.0K | -266.0K |
| Free cash flow | -60.3M | -56.4M | -33.4M | -44.2M | -43.4M | -19.2M | -9.81M |
| Cash from investing | 0 | -254.0K | -769.0K | -3.61M | -498.0K | -560.0K | -266.0K |
| Cash from financing | 6.03M | 13.1M | 58.4M | 15.9M | 109.4M | 93.9M | 21.9M |
| Share buybacks | 16.0M | 109.4M | |||||
| Change in cash | -54.3M | -43.4M | 25.0M | -28.3M | 66.1M | 74.7M | 12.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Nov 13, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Nov 12, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Nov 10, 2026 | Offer document | SEC |
| 425 | Nov 9, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| S-4/A · Registration statement, amended | Oct 26, 2026 | Offer document | SEC |
| S-4 · Registration statement | Sep 22, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 21, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 425 | Aug 21, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 21, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 20, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Jul 31, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 22, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 10-K · Annual report | Mar 27, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2026 | Results | SEC |
| 3 · Initial statement of ownership | Mar 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 24, 2026 | Current report | SEC |
| 8-K · Current report | Feb 13, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 3, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 4, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 4, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 30, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
This page holds 200 of 457 filings. Open Filings
Cap table
Built by 6ix from Werewolf Therapeutics, Inc.’s releases
- Common shares
- 48,601,487
- Fully diluted
- 48,601,487
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 48,601,487 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 48,601,487 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Apr 29, 2021 – May 12, 2025 · Past |
| Briggs Morrison Other companies: CRISPR Therapeutics AG (Director · Since at least Jun 5, 2025); Arvinas, Inc. (Chair of the Arvinas Board of Directors · Since at least Sep 26, 2018); Carisma Therapeutics, Inc. (Director · Mar 7, 2023 – Jun 26, 2024 · Past); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 17, 2021 · Past); Oncorus Inc (Director · Oct 1, 2020 – Oct 1, 2020 · Past); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 11, 2020 · Past); Syndax Pharmaceuticals, Inc. (Director · Mar 2, 2016 – Feb 7, 2024 · Past) | Director · Since at least Apr 29, 2021 |
| Michael Sherman Other companies: Aktis Oncology, Inc. (Director · Since at least Jan 8, 2026); Chimerix Inc (Chief Executive Officer, Director · Jun 20, 2024 – Apr 21, 2025 · Past) | Director · Since at least May 24, 2024 |
| Alon Lazarus Other companies: Keros Therapeutics, Inc. (Director · Apr 7, 2020 – Apr 13, 2020 · Past) | Director · Since at least Dec 23, 2020 |
| Anil Singhal Other companies: TriSalus Life Sciences, Inc. (Director · Aug 10, 2023 – Aug 13, 2024 · Past) | Board member · Since at least Feb 19, 2025 |
| Steven H Bloom Other companies: Verastem, Inc. (Chief Strategy Officer · Nov 8, 2017 – Jan 3, 2019 · Past) | Chief Business Officer · Apr 16, 2025 – May 1, 2025 · Past |
| Daniel J. Hicklin | President, Chief Executive Officer, and Board member · Since at least Dec 8, 2020 |
| Ellen Lubman | Chief Business Officer · Jan 2, 2024 – Jan 2, 2025 · Past |
| Luke Evnin | Director · Since at least Apr 27, 2026 |
| Meeta Chatterjee | Director · Since at least Jun 12, 2025 |
All 16 people
| Person | Seat |
|---|---|
| Michael Atkins | Board member · Since at least Jan 4, 2024 |
| Michael Urban | Vice President of Finance and Corporate Controller · Since at least Feb 13, 2026 |
| Randi Isaacs | Chief Medical Officer · Nov 9, 2020 – Jan 2, 2025 · Past |
| Reid Leonard | Chief Operating Officer · Dec 8, 2020 – Jan 3, 2023 · Past |
| Sakae Asanuma | Director · Dec 23, 2020 – Apr 29, 2021 · Past |
| Timothy W Trost | Chief Financial Officer · Jan 2, 2024 – Jan 2, 2025 · Past |
Log in to ask 6ix AI your own questions about Werewolf Therapeutics, Inc.